1
|
Minecka A, Tarnacka M, Jurkiewicz K, Żakowiecki D, Kamiński K, Kamińska E. Mesoporous Matrices as a Promising New Generation of Carriers for Multipolymorphic Active Pharmaceutical Ingredient Aripiprazole. Mol Pharm 2023; 20:5655-5667. [PMID: 37756382 PMCID: PMC10630940 DOI: 10.1021/acs.molpharmaceut.3c00524] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Revised: 09/09/2023] [Accepted: 09/12/2023] [Indexed: 09/29/2023]
Abstract
The enhancement of the properties (i.e., poor solubility and low bioavailability) of currently available active pharmaceutical ingredients (APIs) is one of the major goals of modern pharmaceutical sciences. Among different strategies, a novel and innovative route to reach this milestone seems to be the application of nanotechnology, especially the incorporation of APIs into porous membranes composed of pores of nanometric size and made of nontoxic materials. Therefore, in this work, taking the antipsychotic API aripiprazole (APZ) infiltrated into various types of mesoporous matrices (anodic aluminum oxide, native, and silanized silica) characterized by similar pore diameters (d = 8-10 nm) as an example, we showed the advantage of incorporated systems in comparison to the bulk substance considering the crystallization kinetics, molecular dynamics, and physical stability. Calorimetric investigations supported by the temperature-dependent X-ray diffraction measurements revealed that in the bulk system the recrystallization of polymorph III, which next is converted to the mixture of forms IV and I, is visible, while in the case of confined samples polymorphic forms I and III of APZ are produced upon heating of the molten API with different rates. Importantly, the two-step crystallization observed in thermograms obtained for the API infiltrated into native silica templates may suggest crystal formation by the interfacial and core molecules. Furthermore, dielectric studies enabled us to conclude that there is no trace of crystallization of spatially restricted API during one month of storage at T = 298 K. Finally, we found that in contrast to the crystalline and amorphous bulk samples, all examined confined systems show a logarithmic increase in API dissolution over time (very close to a prolonged release effect) without any sign of precipitation. Our data demonstrated that mesoporous matrices appear to be interesting candidates as carriers for unstable amorphous APIs, like APZ. In addition to protecting them against crystallization, they can provide the desired prolonged release effect, which may increase the drug concentration in the blood (resulting in higher bioavailability). We believe that the "nanostructirization" in terms of the application of porous membranes as a novel generation of drug carriers might open unique perspectives in the further development of drugs characterized by prolonged release.
Collapse
Affiliation(s)
- Aldona Minecka
- Department
of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences
in Sosnowiec, Medical University of Silesia
in Katowice, 41-200 Sosnowiec, Poland
| | - Magdalena Tarnacka
- A.
Chelkowski Institute of Physics, University
of Silesia in Katowice, 41-500 Chorzow, Poland
| | - Karolina Jurkiewicz
- A.
Chelkowski Institute of Physics, University
of Silesia in Katowice, 41-500 Chorzow, Poland
| | - Daniel Żakowiecki
- Chemische
Fabrik Budenheim KG, Rheinstrasse 27, 55257 Budenheim, Germany
| | - Kamil Kamiński
- A.
Chelkowski Institute of Physics, University
of Silesia in Katowice, 41-500 Chorzow, Poland
| | - Ewa Kamińska
- Department
of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences
in Sosnowiec, Medical University of Silesia
in Katowice, 41-200 Sosnowiec, Poland
| |
Collapse
|
2
|
Minecka A, Chmiel K, Jurkiewicz K, Hachuła B, Łunio R, Żakowiecki D, Hyla K, Milanowski B, Koperwas K, Kamiński K, Paluch M, Kamińska E. Studies on the Vitrified and Cryomilled Bosentan. Mol Pharm 2022; 19:80-90. [PMID: 34851124 PMCID: PMC8728735 DOI: 10.1021/acs.molpharmaceut.1c00613] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
![]()
In this paper, several
experimental techniques [X-ray diffraction,
differential scanning calorimetry (DSC), thermogravimetry, Fourier
transform infrared spectroscopy, and broad-band dielectric spectroscopy]
have been applied to characterize the structural and thermal properties,
H-bonding pattern, and molecular dynamics of amorphous bosentan (BOS)
obtained by vitrification and cryomilling of the monohydrate crystalline
form of this drug. Samples prepared by these two methods were found
to be similar with regard to their internal structure, H-bonding scheme,
and structural (α) dynamics in the supercooled liquid state.
However, based on the analysis of α-relaxation times (dielectric
measurements) predicted for temperatures below the glass-transition
temperature (Tg), as well as DSC thermograms,
it was concluded that the cryoground sample is more aged (and probably
more physically stable) compared to the vitrified one. Interestingly,
such differences in physical properties turned out to be reflected
in the lower intrinsic dissolution rate of BOS obtained by cryomilling
(in the first 15 min of dissolution test) in comparison to the vitrified
drug. Furthermore, we showed that cryogrinding of the crystalline
BOS monohydrate leads to the formation of a nearly anhydrous amorphous
sample. This finding, different from that reported by Megarry et al.
[2011, 346, 1061−106421492830] for trehalose (TRE), was revealed on the
basis of infrared and thermal measurements. Finally, two various hypotheses
explaining water removal upon cryomilling have been discussed in the
manuscript.
Collapse
Affiliation(s)
- Aldona Minecka
- Department of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, ul. Jagiellonska 4, 41-200 Sosnowiec, Poland
| | - Krzysztof Chmiel
- Department of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, ul. Jagiellonska 4, 41-200 Sosnowiec, Poland
| | - Karolina Jurkiewicz
- Institute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów, Poland
| | - Barbara Hachuła
- Institute of Chemistry, University of Silesia in Katowice, 40-006 Katowice, Poland
| | - Rafał Łunio
- Polpharma SA, 83-200 Starogard Gdański, Poland
| | - Daniel Żakowiecki
- Chemische Fabrik Budenheim KG, Rheinstrasse 27, 55257 Budenheim, Germany
| | - Kinga Hyla
- Chair and Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, 60-780 Poznan, Poland
| | - Bartłomiej Milanowski
- Chair and Department of Pharmaceutical Technology, Faculty of Pharmacy, Poznan University of Medical Sciences, 60-780 Poznan, Poland.,GENERICA Pharmaceutical Lab, Regionalne Centrum Zdrowia Sp. z o.o., Na Kępie 3, 64-360 Zbąszyń, Poland
| | - Kajetan Koperwas
- Institute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów, Poland
| | - Kamil Kamiński
- Institute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów, Poland
| | - Marian Paluch
- Institute of Physics, Faculty of Science and Technology, University of Silesia in Katowice, 75 Pułku Piechoty 1, 41-500 Chorzów, Poland
| | - Ewa Kamińska
- Department of Pharmacognosy and Phytochemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, ul. Jagiellonska 4, 41-200 Sosnowiec, Poland
| |
Collapse
|